The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma

Hiroshi Inoue, Masaki Mori, Masayuki Honda, Jian Li, Kenji Shibuta, Koshi Mimori, Hiroaki Ueo, Tsuyoshi Akiyoshi

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Background & Aims The genes MAGE-1 and MAGE-3 both encode melanoma peptide antigens recognized by major histocompatibility complex-restricted cytotoxic T lymphocytes. The antigens may be a target for immunotherapy. There is, however, little information on the expression of these genes in gastric carcinomas. Therefore, the expression of MAGE genes in gastric carcinomas was evaluated. Methods The expression of MAGE-1, MAGE-2, and MAGE-3 genes in tumors and corresponding normal tissue specimens was studied using a reverse-transcription polymerase chain reaction. The results were analyzed according to clinicopathologic factors of the tumor. Results In the 68 gastric carcinomas studied, MAGE-1, MAGE-2, and MAGE-3 messenger RNA were detected in 41%, 31%, and 38%, respectively. Fifty percent of the gastric carcinomas expressed at least one of the MAGE genes. Messenger RNA for the three MAGE proteins was not detected in normal gastric tissue. MAGE gene expression in gastric carcinomas was not associated with a significant clincopathology of the tumor. However, gene expression was lower in mucinous carcinomas (3 of 10). Conclusions MAGE-1, MAGE-2, and MAGE-3 are expressed in a high percentage of gastric carcinomas. These tumor rejection antigens may provide tumor-specific targets for immunotherapy.

Original languageEnglish
Pages (from-to)1522-1525
Number of pages4
JournalGastroenterology
Volume109
Issue number5
DOIs
Publication statusPublished - Jan 1 1995

Fingerprint

Neoplasm Antigens
Stomach
Carcinoma
Genes
Gene Expression
Immunotherapy
Neoplasms
Melanoma-Specific Antigens
Mucinous Adenocarcinoma
Messenger RNA
Cytotoxic T-Lymphocytes
Major Histocompatibility Complex
Reverse Transcription
Antigens
Polymerase Chain Reaction
Peptides
Proteins

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma. / Inoue, Hiroshi; Mori, Masaki; Honda, Masayuki; Li, Jian; Shibuta, Kenji; Mimori, Koshi; Ueo, Hiroaki; Akiyoshi, Tsuyoshi.

In: Gastroenterology, Vol. 109, No. 5, 01.01.1995, p. 1522-1525.

Research output: Contribution to journalArticle

Inoue, Hiroshi ; Mori, Masaki ; Honda, Masayuki ; Li, Jian ; Shibuta, Kenji ; Mimori, Koshi ; Ueo, Hiroaki ; Akiyoshi, Tsuyoshi. / The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma. In: Gastroenterology. 1995 ; Vol. 109, No. 5. pp. 1522-1525.
@article{13650b5ccaaa4d5c981b5007eda0fd98,
title = "The expression of tumor-rejection antigen {"}MAGE{"} genes in human gastric carcinoma",
abstract = "Background & Aims The genes MAGE-1 and MAGE-3 both encode melanoma peptide antigens recognized by major histocompatibility complex-restricted cytotoxic T lymphocytes. The antigens may be a target for immunotherapy. There is, however, little information on the expression of these genes in gastric carcinomas. Therefore, the expression of MAGE genes in gastric carcinomas was evaluated. Methods The expression of MAGE-1, MAGE-2, and MAGE-3 genes in tumors and corresponding normal tissue specimens was studied using a reverse-transcription polymerase chain reaction. The results were analyzed according to clinicopathologic factors of the tumor. Results In the 68 gastric carcinomas studied, MAGE-1, MAGE-2, and MAGE-3 messenger RNA were detected in 41{\%}, 31{\%}, and 38{\%}, respectively. Fifty percent of the gastric carcinomas expressed at least one of the MAGE genes. Messenger RNA for the three MAGE proteins was not detected in normal gastric tissue. MAGE gene expression in gastric carcinomas was not associated with a significant clincopathology of the tumor. However, gene expression was lower in mucinous carcinomas (3 of 10). Conclusions MAGE-1, MAGE-2, and MAGE-3 are expressed in a high percentage of gastric carcinomas. These tumor rejection antigens may provide tumor-specific targets for immunotherapy.",
author = "Hiroshi Inoue and Masaki Mori and Masayuki Honda and Jian Li and Kenji Shibuta and Koshi Mimori and Hiroaki Ueo and Tsuyoshi Akiyoshi",
year = "1995",
month = "1",
day = "1",
doi = "10.1016/0016-5085(95)90639-8",
language = "English",
volume = "109",
pages = "1522--1525",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma

AU - Inoue, Hiroshi

AU - Mori, Masaki

AU - Honda, Masayuki

AU - Li, Jian

AU - Shibuta, Kenji

AU - Mimori, Koshi

AU - Ueo, Hiroaki

AU - Akiyoshi, Tsuyoshi

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Background & Aims The genes MAGE-1 and MAGE-3 both encode melanoma peptide antigens recognized by major histocompatibility complex-restricted cytotoxic T lymphocytes. The antigens may be a target for immunotherapy. There is, however, little information on the expression of these genes in gastric carcinomas. Therefore, the expression of MAGE genes in gastric carcinomas was evaluated. Methods The expression of MAGE-1, MAGE-2, and MAGE-3 genes in tumors and corresponding normal tissue specimens was studied using a reverse-transcription polymerase chain reaction. The results were analyzed according to clinicopathologic factors of the tumor. Results In the 68 gastric carcinomas studied, MAGE-1, MAGE-2, and MAGE-3 messenger RNA were detected in 41%, 31%, and 38%, respectively. Fifty percent of the gastric carcinomas expressed at least one of the MAGE genes. Messenger RNA for the three MAGE proteins was not detected in normal gastric tissue. MAGE gene expression in gastric carcinomas was not associated with a significant clincopathology of the tumor. However, gene expression was lower in mucinous carcinomas (3 of 10). Conclusions MAGE-1, MAGE-2, and MAGE-3 are expressed in a high percentage of gastric carcinomas. These tumor rejection antigens may provide tumor-specific targets for immunotherapy.

AB - Background & Aims The genes MAGE-1 and MAGE-3 both encode melanoma peptide antigens recognized by major histocompatibility complex-restricted cytotoxic T lymphocytes. The antigens may be a target for immunotherapy. There is, however, little information on the expression of these genes in gastric carcinomas. Therefore, the expression of MAGE genes in gastric carcinomas was evaluated. Methods The expression of MAGE-1, MAGE-2, and MAGE-3 genes in tumors and corresponding normal tissue specimens was studied using a reverse-transcription polymerase chain reaction. The results were analyzed according to clinicopathologic factors of the tumor. Results In the 68 gastric carcinomas studied, MAGE-1, MAGE-2, and MAGE-3 messenger RNA were detected in 41%, 31%, and 38%, respectively. Fifty percent of the gastric carcinomas expressed at least one of the MAGE genes. Messenger RNA for the three MAGE proteins was not detected in normal gastric tissue. MAGE gene expression in gastric carcinomas was not associated with a significant clincopathology of the tumor. However, gene expression was lower in mucinous carcinomas (3 of 10). Conclusions MAGE-1, MAGE-2, and MAGE-3 are expressed in a high percentage of gastric carcinomas. These tumor rejection antigens may provide tumor-specific targets for immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0028829525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028829525&partnerID=8YFLogxK

U2 - 10.1016/0016-5085(95)90639-8

DO - 10.1016/0016-5085(95)90639-8

M3 - Article

C2 - 7557134

AN - SCOPUS:0028829525

VL - 109

SP - 1522

EP - 1525

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 5

ER -